Prostate cancer (PCa) is the most frequently diagnosed type of cancer among males. Deaths resulting from PCa occur due to the metastatic outcome rather than primary tumors. The increase in the expression of voltage-gated sodium channels (VGSCs) located on the cell membrane promotes the motility of cells and supports the metastatic potential. To this end, the inhibition effects of cells with metastatic characteristics on the motility of cells are examined using agents/drugs that block VGSCs. Mat-LyLu cells, a rat PCa cell line with a highly metastatic character, are known to have a high expression of VGSCs. Studies conducted with RIL, acting as a VGSC blocker, have shown that human PCa cell proliferation is inhibited. In this study, the effects of RIL on the lateral motility of rat PCa Mat-LyLu cells with the high VGSC expression will be investigated.
Mat-LyLu cells were cultured in RPMI-1640 with serum (FBS). The trypan blue method was used to assess the toxicity of RIL on Mat-LyLu cells and cell proliferation was determined by the MTT method. 'Wound healing' was applied to evaluate the lateral motility of the cells. 1, 3, and 5 μM RIL, that have no effect on cell proliferation, and tetrodotoxin (TTX), as a positive control, were used in the investigation of lateral motility. Furthermore, the control-DMSO group was added to all experiments. All experiments were repeated at least three times, and were evaluated statistically.
The result of the RIL administration to Mat-LyLu cells showed that the 48h results from the control and experimental groups (1, 3 and 5 μM) did not affect the cell proliferation. However, with higher RIL concentrations, such as 10 and 20 μM, cell proliferation was significantly reduced. In the positive control group with TTX, a specific VGSC blocker, lateral motility was significantly inhibited. The lateral motility of Mat-LyLu cells in the experimental groups (1, 3 and 5 μM) decreased (P
The data obtained from the study show that RIL inhibits the lateral motility of highly metastatic rat PCa cells, Mat-LyLu, by blocking VGSCs. These first in vitro results demonstrating the potential of RIL to be used as an anti-metastatic drug suggest that the effect of RIL on the VGSCs should also be assessed in vivo.
Clinical trial identification
Legal entity responsible for the study
Istanbul University Scientific Research Projects
All authors have declared no conflicts of interest.